ClinicalTrials.gg
RecruitingNCT07298421SIBERITE-PEDSUpdated Nov 5, 2026

A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in Children With Moderately to Severely Active Crohn's Disease

A Phase 3 interventional study of Afimkibart in Moderately to Severely Active Crohns Disease, sponsored by Hoffmann-La Roche. Recruiting at 19 sites in 8 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 5, 20265 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
2 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Crohn Disease by Hoffmann-La Roche — 3 open to participants now, 4 under way, 3 of them phase 3. Crohn Disease · Hoffmann-La Roche.

Planned enrollment
6th of 10
100 · median 122
Started
2026
the only one that year
Phase 3
5 of 10
3 open now
Registered
10th of 10
by date

Among the 10 studies in Crohn Disease by Hoffmann-La Roche, this one is the 6th largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 3, and was the 10th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

3 of the 10 studies in Crohn Disease by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 2 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Crohn Disease by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This phase III, double-blind, multi-center treat-through study will evaluate the efficacy and safety of Afimkibart (also known as RO7790121) in children with moderately to severely active Crohn's Disease (CD).

03

Conditions studied

  • Moderately to Severely Active Crohns Disease

Browse trials for

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight >= 10 kilogram (kg)
  • Active CD confirmed by endoscopy (ileocolonoscopy)
  • Moderately to severely active CD, defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score >= 30, and Simple Endoscopic Score Crohn's Disease (SES-CD) >=6 (or >=4 for isolated ileal disease) confirmed through centrally-read ileocolonoscopy
  • Inadequate response, loss of response, and/or intolerance to at least one of the following conventional therapies (aminosalicylates, and/or ) or advanced therapies (including anti-tumor necrosis factor, anti-interleukin, anti-integrin, or Janus Kinase (JAK) inhibitors)

Exclusion criteria

Exclusion Criteria:

  • Monogenic disorder pertaining to infant onset Inflammatory Bowel Disease (IBD)
  • History of >= 3 bowel resections: > 2 missing segments of the following five segments: terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum
  • Current diagnosis of ulcerative colitis (UC), abdominal/intraabdominal/perianal fistula and/or abscess, indeterminant colitis, IBD-unclassified, microscopic colitis, ischemic colitis, infectious colitis, radiation colitis, or active diverticular disease.
  • Symptomatic bowel strictures, fulminant colitis, or toxic megacolon
  • Presence of abdominal or perianal abscess
  • Current diagnosis or suspicion of primary sclerosing cholangitis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Afimkibart Dose A

    Participants will receive Afimkibart intravenously (IV) followed by Afimkibart subcutaneous (SC) injection.

    Drug: Afimkibart

  • Experimental
    Afimkibart Dose B

    Participants will receive Afimkibart IV followed by Afimkibart SC.

    Drug: Afimkibart

Interventions

  • Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.

    Also known as: RO7790121, PF-06480605, RVT-3101

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Remission per Pediatric Crohn's Disease Activity Index (PCDAI)

    Time frame: At Week 52

  2. Percentage of Participants With Endoscopic Response

    Time frame: At Week 52

Secondary outcomes

  1. Percentage of Participants With Clinical Remission

    Time frame: At Week 12 and Week 52

  2. Percentage of Participants With Clinical Response

    Time frame: At Week 12 and Week 52

  3. Percentage of Participants With CDAI Remission

    Time frame: At Week 12 and Week 52

  4. Change From Baseline in Fecal Calprotectin

    Time frame: Baseline, Week 12 and Week 52

  5. Change From Baseline in Mucosal Inflammation Noninvasive Index (MINI) Score

    Time frame: Baseline, Week 12 and Week 52

  6. Percentage of Participants With Endoscopic Remission

    Time frame: At Week 52

  7. Percentage of Participants With Corticosteroid-Free Clinical Remission

    Time frame: At Week 52

  8. Percentage of Participants with Maintenance of Remission

    Time frame: At Week 12 and Week 52

  9. Percentage of Participants With Histologic Improvement

    Time frame: At Week 52

  10. Percentage of Participants With Ulcer-Free Endoscopy

    Time frame: At Week 52

  11. Incidence and Severity of Adverse Events (AEs)

    Time frame: Up to Approximately 5.5 Years

  12. Serum Concentration of Afimkibart

    Time frame: Up to Approximately 5.5 Years

07

Study locations

19 of 19 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for May 2030, 45 months after the start.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's planned 45 months is close to that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2025
First posted
Dec 23, 2025
StartActual
Aug 18, 2026
Primary completionEst.
May 31, 2030
CompletionEst.
May 30, 2031
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added
Show 5 added (2 United Kingdom, 1 Australia, 1 Brazil, 1 United States)
  • Mater Hospital Brisbane · South Brisbane, Australia
  • Santa Casa de Misericordia de Porto Alegre · Porto Alegre, Brazil
  • King's College Hospital · London, United Kingdom
  • Texas Digestive Specialists · Harlingen, United States
  • Birmingham Children's Hospital · Birmingham, United Kingdom
across 2 updates, Oct 6, 2026 – Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    2 sites added
    Show 2 added (1 United States, 1 United Kingdom)
    • Texas Digestive Specialists · Harlingen, United States
    • Birmingham Children's Hospital · Birmingham, United Kingdom
    + 1 other change: verification date
  2. Oct 6, 2026
    3 sites added
    Show 3 added (1 Australia, 1 Brazil, 1 United Kingdom)
    • Mater Hospital Brisbane · South Brisbane, Australia
    • Santa Casa de Misericordia de Porto Alegre · Porto Alegre, Brazil
    • King's College Hospital · London, United Kingdom
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07298421
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 23, 2025
Start date
Aug 18, 2026
Primary completion
May 31, 2030 (estimated)
Completion
May 30, 2031 (estimated)
Last update
Nov 5, 2026

Study contacts

Reference Study ID Number: CP45906 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimkibart

Start the discussion